07/30/2021 8:10 AM
Clarín.com
Society
Updated 07/30/2021 8:38 AM
The previous results of the investigation of the combination of the Russian anticovid vaccines
Sputnik V
and the British
AstraZeneca
that is carried out in Azerbaijan show its high level of safety and the lack of serious adverse reactions, reported this Friday the Direct Investment Fund of Russia (FIDR).
"The intermediate analysis of the data shows
high safety indicators of
the combined use of the drugs: no serious undesirable phenomena or cases of infection with coronavirus are observed after vaccination," the FIDR, which promotes and markets the Russian vaccine, said in a statement. .
The vaccine combination was applied to a small group of
50 volunteers
in Azerbaijan.
The
phases I and II
of the clinical trials of this "cocktail" are scheduled to last until
March 2022
.
According to the Gamaleya Center, developer of Sputnik V, in a vaccine that uses different human adenoviruses as vectors in its two components, the first of them can be used as a single-dose preparation, which was given the name of
Sputnik Light
.
Russian scientists argue that the use of
two different vectors
provides
longer immunity
than two-dose vaccines using the same vector.
At the moment clinical studies of the combination are also being carried out in the United Arab Emirates and Argentina.
According to the FIDR, the first results of the tests carried out in Azerbaijan will be published next August.
Argentina adds Modern
The
doses of Moderna
will be included in the study of combined schemes carried out by the Ministry of Health to authorize heterologous vaccination schemes against the coronavirus, that is, the possibility of using
vaccines from different laboratories
in the same immunization.
"We have defined the incorporation of the Modern vaccine in the studies that seek to determine the safety and immunity in the
combination of vaccines,
" said Minister Carla Vizzotti, adding that "advancing in the production of scientific evidence in this regard is very important in order to count with a greater range of possibilities to achieve complete (vaccination) schedules in the shortest possible time ”.
The study in question is
"collaborative and federal"
, and is coordinated with the participating jurisdictions (Buenos Aires, Córdoba, La Rioja, Mendoza and San Luis) and researchers from the National Council for Scientific and Technical Research (CONICET).
The Ministry of Health joined Moderna in the vaccine combination study.
Photo: AP.
The scientific work seeks "to have national evidence for decision-making based on the analysis of immunogenicity and safety of the use of different doses in the same scheme," as specified in the official statement.
Until now, the dose combinations of
AstraZeneca
, the Chinese
Sinopharm
and the Russian
Sputnik V
were under study
, the latter being the one with the longest delay for second applications.
The study involves
volunteers over 18 years of age
vaccinated with a dose of one of these three vaccines "up to 60 days prior to enrollment", with and without identified risk factors for coronavirus.
Moderna's vaccines arrived in Argentina on July 16, through a donation from the United States government.
There are 3.5 million doses.
They were received on that occasion by the Chief of Staff, Santiago Cafiero, and the Charge d'Affaires of the United States Embassy, MaryKay Carlson.
EFE source
AFG
Look also
Sputnik V, "stranded": it has been without approval in Europe for five months and the WHO does not authorize it
In the absence of second doses of Sputnik V, Bolivia analyzes combining vaccines
